Nanobiotix (LTS:0QAV) Institutional Ownership : 4.47% (As of Dec. 14, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Nanobiotix Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Nanobiotix's institutional ownership is 4.47%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Nanobiotix's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Nanobiotix's Float Percentage Of Total Shares Outstanding is 85.45%.

Nanobiotix Institutional Ownership Historical Data

The historical data trend for Nanobiotix's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanobiotix Institutional Ownership Chart

Nanobiotix Historical Data

The historical data trend for Nanobiotix can be seen below:

	2024-02-29	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30
Institutional Ownership	2.72	2.73	2.82	2.10	2.04	2.04	2.04	5.26	4.93	4.47

Nanobiotix Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Nanobiotix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanobiotix SA (LTS:0QAV) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

NBTX:USA NANO:France 5NRA:Germany

Address

60 Rue de Wattignies, Paris, FRA, 75012

Website

https://www.nanobiotix.com

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Nanobiotix Headlines

No Headlines